Should I Buy TMDX? TMDX 2026 Analysis

Should You Buy Transmedics Group Inc (TMDX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

135.500

1 Day change

1.26%

52 Week Range

156.000

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

TransMedics Group Inc (TMDX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, FDA approval for its ENHANCE Heart trial, and positive analyst ratings outweigh the current technical weakness and minor competition concerns. The stock is well-positioned for long-term growth.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is at 34.062, nearing oversold territory but still neutral. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 128.538), with resistance at 139.016. Overall, the technical indicators suggest a short-term bearish trend but do not negate long-term potential.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market, with more interest in calls than puts.

Technical Summary

Sell

Buy

Positive Catalysts

FDA approval for the Next-Generation OCS ENHANCE Heart trial, which is a significant milestone in organ transplant technology.
Strong financial performance in Q3 2025, with revenue up 32.24% YoY and net income up 476.83% YoY.
Analysts remain bullish, with multiple buy ratings and price targets ranging from $135 to $
Positive organ transplant volume trends, particularly in liver transplants.

Neutral/Negative Catalysts

Short-term technical weakness with bearish momentum and a recent selloff.
Potential competition from Bridge to Life's VitaSmart system, although analysts do not view it as a significant threat.

Financial Performance

In Q3 2025, TransMedics reported a 32.24% YoY increase in revenue to $143.82M, a 476.83% YoY increase in net income to $24.32M, and a 400% YoY increase in EPS to $0.6. Gross margin also improved to 58.74%, up 5.17% YoY, indicating strong operational efficiency and profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on TMDX. TD Cowen, Piper Sandler, Canaccord, and Needham have reiterated buy ratings with price targets ranging from $135 to $170. Analysts highlight TransMedics' dominance in the organ transplant market and view the recent selloff as unwarranted. Morgan Stanley is neutral with an Equal Weight rating and a $135 price target.

11 Analyst Rating

Wall Street analysts forecast TMDX stock price to rise

9 Buy

2 Hold

0 Sell

Strong Buy

Current: 133.820

Low

115

Averages

147.8

High

170

Current: 133.820

Low

115

Averages

147.8

High

170

TD Cowen

Buy

maintain

$170

AI Analysis

2026-01-21

Reason

TD Cowen

Price Target

$170

AI Analysis

2026-01-21

maintain

Buy

Reason

TD Cowen says TransMedics shares are under pressure after Bridge to Life's VitaSmart received FDA clearance for liver transplantation. While VitaSmart is "technically competition" to TransMedics' OCS Liver, the system employs a back-to-base model using static cold storage, followed by hyperoxygenated perfusion in a bowl, the analyst tells investors in a research note. As a result, TD does not view VitaSmart as a threat to OCS Liver. Bridge to Life's system is "vastly different" from TransMedics' as it is not portable and does not allow surgeons to utilize biomarkers to assess organ function in the way that OCS Liver does, the firm contends. It continues to think TransMedics will maintain its dominance as new machine perfusion options come to market for liver. The firm views the selloff in shares today as unwarranted and reiterates a Buy rating on TransMedics with a $170 price target. The stock in afternoon trading is down 5% to $134.39.

Piper Sandler

Matt O'Brien

Overweight

maintain

$140

2026-01-02

Reason

Piper Sandler

Matt O'Brien

Price Target

$140

2026-01-02

maintain

Overweight

Reason

Piper Sandler analyst Matt O'Brien notes that every month, the firm tracks organ transplant volumes and the number of flights taken by TransMedics' medical jet fleet. Transplant volumes grew low single-digit in Q4 2025 versus Q3 2025. Liver, which the company is closely tied to, showed a strong 4.2% increase quarter-to-date. Piper keeps in mind that the Street is still expecting nearly 10% sequential growth in product sales in Q4 2025, which appears achievable to it based on machine perfusion share gains though room for upside seems limited. While the firm's model implies that service revenues may fall just short of expectations, it is within a reasonable margin of error for potential modest upside. Thus overall, Piper believes the Street's service revenue target is achievable, with modest downside risk and upside potential. The firm has an Overweight rating on the shares with a price target of $140.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TMDX

Unlock Now

TMDX Should I Buy

TMDX Should I Buy

Should You Buy Transmedics Group Inc (TMDX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch